Who are Epirubicin, Paclitaxel, Filgrastim's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-paclitaxel-filgrastim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epirubicin, Paclitaxel, Filgrastim — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epirubicin, Paclitaxel, Filgrastim (Epirubicin, Paclitaxel, Filgrastim) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (anthracycline + taxane + growth factor). Area: Oncology.

phase 3 Chemotherapy combination (anthracycline + taxane + growth factor) DNA (epirubicin); microtubules (paclitaxel); G-CSF receptor (filgrastim) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epirubicin, Paclitaxel, Filgrastim (Epirubicin, Paclitaxel, Filgrastim) — North Eastern German Society of Gynaecological Oncology. This combination regimen uses an anthracycline chemotherapy agent and a taxane to damage cancer cell DNA and disrupt microtubule formation, supported by a growth factor to maintain bone marrow function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epirubicin, Paclitaxel, Filgrastim TARGET	Epirubicin, Paclitaxel, Filgrastim	North Eastern German Society of Gynaecological Oncology	phase 3	Chemotherapy combination (anthracycline + taxane + growth factor)	DNA (epirubicin); microtubules (paclitaxel); G-CSF receptor (filgrastim)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (anthracycline + taxane + growth factor) class)

North Eastern German Society of Gynaecological Oncology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epirubicin, Paclitaxel, Filgrastim — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-paclitaxel-filgrastim. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab